BACKGROUND: Thyroid cancers have increased dramatically over the past few decades. Comorbidities may be important, and previous studies have indicated elevated second cancer risk after initial primary thyroid cancers. This study examined the risk of second cancers after development of a thyroid cancer, primary utilizing the Surveillance, Epidemiology, and End Results (SEER) program database. METHODS: The cohort consisted of men and women diagnosed with first primary thyroid cancer who were reported to a SEER database in 1973-2008 (n=52,103). Standardized incidence ratios (SIR) were calculated for all secondary cancers. Confidence intervals and p-values are at 0.05 significance alpha level and are two-sided based on Poisson exact methods. RESULTS: In this cohort, 4457 individuals developed second cancers. The risk of developing second cancers after a primary thyroid cancer varied from 10% to 150% depending on different cancer types. Cancers in all sites, breast, skin, prostate, kidney, brain, salivary gland, second thyroid, lymphoma, myeloma, and leukemia were elevated. The magnitude of the risk varied by histology, tumor size, calendar year of first primary thyroid cancer diagnosis, and the treatment of the primary thyroid cancer. The risk of a second cancer was elevated in patients whose first primary thyroid carcinomas were small, or were diagnosed after 1994, or in whom some form of radiation treatment was administered. CONCLUSIONS: This large population-based analysis of second cancers among thyroid cancer patients suggests that there was an increase of second cancers in all sites, and the most commonly elevated second cancers were the salivary gland and kidney. Additionally, the increase in second cancers in patients with recently diagnosed thyroid microcarcinomas (<10 mm) suggests that aggressive radiation treatment of the first primary thyroid cancer, the environment, and genetic susceptibility, may increase the risk of a second cancer.
BACKGROUND:Thyroid cancers have increased dramatically over the past few decades. Comorbidities may be important, and previous studies have indicated elevated second cancer risk after initial primary thyroid cancers. This study examined the risk of second cancers after development of a thyroid cancer, primary utilizing the Surveillance, Epidemiology, and End Results (SEER) program database. METHODS: The cohort consisted of men and women diagnosed with first primary thyroid cancer who were reported to a SEER database in 1973-2008 (n=52,103). Standardized incidence ratios (SIR) were calculated for all secondary cancers. Confidence intervals and p-values are at 0.05 significance alpha level and are two-sided based on Poisson exact methods. RESULTS: In this cohort, 4457 individuals developed second cancers. The risk of developing second cancers after a primary thyroid cancer varied from 10% to 150% depending on different cancer types. Cancers in all sites, breast, skin, prostate, kidney, brain, salivary gland, second thyroid, lymphoma, myeloma, and leukemia were elevated. The magnitude of the risk varied by histology, tumor size, calendar year of first primary thyroid cancer diagnosis, and the treatment of the primary thyroid cancer. The risk of a second cancer was elevated in patients whose first primary thyroid carcinomas were small, or were diagnosed after 1994, or in whom some form of radiation treatment was administered. CONCLUSIONS: This large population-based analysis of second cancers among thyroid cancerpatients suggests that there was an increase of second cancers in all sites, and the most commonly elevated second cancers were the salivary gland and kidney. Additionally, the increase in second cancers in patients with recently diagnosed thyroid microcarcinomas (<10 mm) suggests that aggressive radiation treatment of the first primary thyroid cancer, the environment, and genetic susceptibility, may increase the risk of a second cancer.
Authors: M Montani; A M Schmitt; S Schmid; T Locher; P Saremaslani; P U Heitz; P Komminoth; A Perren Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: Shu-Chun Chuang; Mia Hashibe; Guo-Pei Yu; Anh D Le; Wei Cao; Eric L Hurwitz; Jian-Yu Rao; Alfred I Neugut; Zuo-Feng Zhang Journal: Cancer Lett Date: 2005-07-21 Impact factor: 8.679
Authors: Thekkepat C Sandeep; Mark W J Strachan; Rebecca M Reynolds; David H Brewster; Ghislaine Scélo; Eero Pukkala; Kari Hemminki; Aage Anderson; Elizabeth Tracey; Søren Friis; Mary L McBride; Chia Kee-Seng; Vera Pompe-Kirn; Erich V Kliewer; Jon M Tonita; Jon G Jonasson; Carmen Martos; Paolo Boffetta; Paul Brennan Journal: J Clin Endocrinol Metab Date: 2006-02-14 Impact factor: 5.958
Authors: Alf Inge Hellevik; Bjørn Olav Asvold; Trine Bjøro; Pål R Romundstad; Tom Ivar L Nilsen; Lars J Vatten Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01-20 Impact factor: 4.254
Authors: John P Hanley; Erin Jackson; Leslie A Morrissey; Donna M Rizzo; Brian L Sprague; Indra Neil Sarkar; Frances E Carr Journal: Thyroid Date: 2015-06-02 Impact factor: 6.568
Authors: Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254
Authors: Alessandro De Luca; Federico Frusone; Massimo Vergine; Rosario Cocchiara; Giuseppe La Torre; Laura Ballesio; Massimo Monti; Maria Ida Amabile Journal: In Vivo Date: 2019 Jul-Aug Impact factor: 2.155
Authors: Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed Journal: Int J Clin Oncol Date: 2018-02-28 Impact factor: 3.402
Authors: Christopher Kim; Huang Huang; Nan Zhao; Catherine C Lerro; Min Dai; Yingtai Chen; Ni Li; Shuangge Ma; Robert Udelsman; Yawei Zhang Journal: Int J Vitam Nutr Res Date: 2017-04-24 Impact factor: 1.784
Authors: Tommi T Hakala; Juhani A Sand; Arja Jukkola; Heini S Huhtala; Saara Metso; Pirkko-Liisa Kellokumpu-Lehtinen Journal: Int J Clin Oncol Date: 2015-09-26 Impact factor: 3.402